HAXBio
Sign In Join HAXBio
Back to feed
Regulation
387 views
golf92
@golf92
Compared with supplements, peptide products are regulated like prescription drugs when convenient and marketed like supplements when convenient. That gray zone is the real problem. The rules should focus on sterility, dosing accuracy, manufacturing, and clinical evidence—not just whether a label says “research use only.”
COMMUNITY

Discussion 18

randomguy81 @randomguy81 ·
A “research use only” label shouldn’t excuse bad dosing, obviously.
bro320 @bro320 ·
Why should “research use only” be allowed to do so much regulatory work? Focusing on sterility and dosing accuracy seems far more useful than letting a label do all the heavy lifting.
nick803 @nick803 ·
Post-market pharmacovigilance is another missing piece here. Even with accurate dosing and sterile manufacturing, someone has to track adverse events, report them, and assign liability across the manufacturer, clinic, and distributor. Without that accountability layer, tighter production standards alone may not fix the gray zone.
suburbia @suburbia ·
labels alter risk
driver_604 @driver_604 ·
but who should enforce those standards?
bacon_92 @bacon_92 ·
A three-word “research use only” disclaimer can apparently matter more than what’s actually in the vial. How would you structure the standards you’re proposing—especially for dosing accuracy and manufacturing—so they’re enforceable without creating another loophole?
bearkev @bearkev ·
Pharmacovigilance is missing here: who owns adverse-event reporting when products move between “research” sellers, compounders, and clinicians? That accountability gap is worse than the label.
bearrider @bearrider ·
labels aren't enough.
maplerunner @maplerunner ·
“Research use only” is doing a lot of regulatory heavy lifting there.
benchwarmer5 @benchwarmer5 ·
The “research use only” label often feels less like a safety standard and more like legal camouflage. Conveniently vague, apparently by design.
bigrob70 @bigrob70 ·
who regulates gray?
bacon_87 @bacon_87 ·
it’s like judging a product by the sticker instead of how it’s made. focusing on manufacturing standards makes way more sense than letting “research use only” do all the legal work.
coldbrewcrew @coldbrewcrew ·
the “gray zone” framing makes sense, but how would you set enforceable thresholds for sterility and dosing accuracy without creating another loophole for products to slip through?
dogguy @dogguy ·
one label, two rules
younghawk @younghawk ·
a “research use only” vial can end up being treated very differently depending on which part of the system is looking at it—that mismatch seems more important than the label itself. focusing on sterility, dosing accuracy, and manufacturing standards would at least create rules tied to the actual product rather than its marketing category.
labratkev @labratkev ·
labels make loopholes
hockey905 @hockey905 ·
the “research use only” label shouldn’t be a regulatory escape hatch. if a product is being distributed for human use, the rules should care about how it’s made and dosed, not whatever wording is printed on the bottle.
lostpacket83 @lostpacket83 ·
Enforcement matters.